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Introduction
Brain metastases (BM) develop in up to 20–40% of patients 
diagnosed with cancer, and the incidence is increasing as 
cancer patients are living longer with improving systemic 
therapy [1, 2]. Radiation therapy (RT) is an integral com-
ponent of the treatment of BM to improve local control, 
and in certain instances, overall survival (OS). Whole- brain 
radiation therapy (WBRT) has traditionally been the standard 
for patients with multiple BM. However, there has been a 
trend toward increased use of stereotactic radiosurgery (SRS) 
for management of patients with single or <4 BM [3, 4].
The efficacy and toxicity of WBRT in comparison with 
and in addition to SRS have been evaluated in a rand-
omized fashion and in a meta- analysis [5]. Recent trials 
have shown the addition of WBRT to SRS does not 
improve survival outcomes, and WBRT causes significant 
declines in neurocognition and overall quality of life (QOL) 
for patients with 1–3 BM [6, 7]. For example, Alliance 
trial N0574 randomized patients with 1–3 BM to SRS 
versus SRS with WBRT and found no statistically signifi-
cant difference in median OS, 10.4 months versus 
7.4 months, respectively (P = 0.92). While WBRT after 
SRS improved local and regional control, it had no impact 
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Abstract
Stereotactic Radiosurgery (SRS) is considered standard of care for patients with 
1–3 brain metastases (BM). Recent observational studies have shown equivalent 
OS in patients with 5+ BM compared to those with 2–4, suggesting SRS alone 
may be appropriate in these patients. We aim to review outcomes of patients 
treated with SRS with 2–4 versus 5+ BM. This analysis included consecutive 
patients from 1994 to 2015 treated with SRS. Of 1017 patients, we excluded 
patients with a single BM and patients without adequate survival data, resulting 
in 391 patients. All risk factors were entered into univariate analysis using Cox 
proportional hazards model, and significant factors were entered into multivari-
ate analysis (MVA). We additionally analyzed outcomes after excluding patients 
with prior surgery or whole- brain radiotherapy (WBRT). Median follow- up was 
7.1 months. Median KPS was 90, mean age was 59, and most common histolo-
gies were melanoma and lung. Median tumor volume was 3.41 cc. Patients 
with 2–4 BM had a median OS of 8.1 months compared to 6.2 months for 
those with 5+ BM (P = 0.0136). On MVA, tumor volume, KPS, and histology 
remained significant for OS, whereas lesion number did not. Similar results 
were found when excluding patients with prior surgery or WBRT. Rather than 
lesion number, the strongest prognostic factors for patients undergoing SRS 
were tumor volume >10 cc, KPS, and histology. BM number may therefore 
not be the most important criterion for candidacy for SRS. Patients with 5 or 
more BM should be considered for SRS.
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on OS and was associated with decreased cognitive func-
tion and decreased quality of life 3 months after treatment 
[7].
Furthermore, SRS can be performed in a single fraction 
which is more convenient for patients. Often, patients 
will require an interruption in systemic therapy while 
undergoing WBRT due to concern regarding increased 
toxicity with concurrent treatment. Thus, patients treated 
with SRS may end up ultimately receiving more systemic 
therapy in comparison with those undergoing WBRT [8]. 
This is an especially important consideration in the age 
of newer targeted agents that can significantly impact 
survival and disease burden.
Stereotactic radiosurgery alone or in combination with 
other modalities is therefore generally accepted as the 
standard of care for patients with 1–3 BM. However, 
debate and uncertainty regarding the optimal management 
of patients with 4–5 or more BM remains. Yamamoto 
et al. have suggested equivalent outcomes for patients 
with four or more BM treated with SRS in comparison 
with patients with fewer BM [9, 10]. There are no pub-
lished randomized trials for SRS versus WBRT for patients 
with five or more BM.
In the absence of level 1 evidence addressing the optimal 
management of patients presenting with multiple BM, the 
aim of this study was to compare OS and identify prog-
nostic factors in patients with 2–4 versus 5 or more BM. 
This analysis further elucidates considerations for the use 
of SRS in patients with more than 4 BM by reviewing 




Institutional review board approval was obtained and 
retrospective review was performed of all consecutive 
patients with BM treated with SRS at our institution from 
1994 to 2015. We included patients with two or more 
treated BM, and excluded patients who were missing criti-
cal baseline, treatment, or survival information. We addi-
tionally analyzed outcomes after excluding patients who 
were treated with prior neurosurgical resection or WBRT. 
We obtained patient and treatment information from 
electronic medical records and survival data from the 
institutional cancer registry.
Radiation delivery
All patients were treated with single- fraction Gamma Knife 
radiosurgery. Gamma Knife (Elekta Instruments Inc.) 
Model U was used from 1994 to 2000, Model C was 
used from 2000 to 2008, and Perfexion was used from 
2008 to 2015. All patients were immobilized with a ste-
reotactic head frame. The frame application was performed 
by a neurosurgeon utilizing four pins affixed to the cra-
nium after the patient was provided conscious sedation 
by a member of the anesthesia team. Contrast- enhanced 
thin slice magnetic resonance imaging (MRI) of the brain 
was then performed for target delineation and treatment 
planning.
Dose prescription was at the discretion of the treating 
team and in general accordance with RTOG 90- 05. For 
tumor diameter <2 cm, prescription was 20–24 Gy typi-
cally to 50% isodoline line. For tumors >2 cm and <3 cm 
diameter, dose was generally 18 Gy to 50% isodose line. 
For tumors >3 cm, we typically prescribe 15 Gy to 50% 
isodoseline. This prescription guideline is not modified 
for various primary cancers including nonsmall cell lung 
cancer, breast cancer, melanoma, renal cell cancer, and 
colorectal cancer. Tumor equivalent volumes are converted 
using the formula for volume of a sphere, (4/3) * π * 
r3. A 2- cm- diameter cutoff corresponds to 4.19 cc volu-
metric cutoff. A 3- cm- diameter cutoff corresponds to a 
14.1 cc volumetric cutoff. The decision to leave BM 
untreated at the time of SRS was per the radiation oncolo-
gist and neurosurgeon at the time of treatment, with 
generally small and asymptomatic BM as lesions less likely 
to be treated [11].
Statistical analysis
The primary endpoint was overall survival (OS) in months. 
Time was calculated from the date of initial SRS treat-
ment to the date of death. Censoring occurred at the 
date the patient was last known to be alive. All risk fac-
tors were defined at the time of initial SRS. Analyzed 
risk factors for survival included age, sex, tumor histology, 
performance status, graded prognostic assessment (GPA) 
score, recursive partitioning analysis (RPA) class, synchro-
nous or metachronous diagnosis of BM, increase in number 
of BM from initial consultation to treatment, untreated 
BM, infratentorial BM, number of BM treated, total tumor 
volume (continuous and categorical <5 cc, 5–10 cc, >10 cc), 
and SRS dose.
Performance status was graded with the Karnofsky 
Performance Score (KPS) on a scale of 0 to 100. GPA 
was scored from 0 to 4 based on age, KPS, number of 
BM, and the presence of extracranial metastases [12]. RPA 
was scored from 1 to 3 based on age, KPS, control of 
primary disease, and the presence of extracranial metastases 
[13]. Synchronous diagnosis of BM was defined as discovery 
of BM within 3 months of the diagnosis of the primary 
cancer. Progression of BM was defined as an increase in 
number of identified BM between the initial diagnostic 
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MRI and the MRI on the day of SRS treatment. Patients 
were defined as having untreated BM if not all identified 
BM were targeted with SRS. The total tumor volume is 
the total volume of BM treated with SRS as measured on 
MRI using Leksell GammaPlan (Elekta Inc. Stockholm, 
Sweden) software.
Baseline variables were compared using the Wilcoxon 
rank sum test, Pearson’s chi- squared test, and Fisher’s exact 
test. OS was analyzed using the Kaplan–Meier method with 
significance testing with the log rank test. We performed 
two analyses; Analysis 1 included all patients. Analysis 2 
excluded patients with prior neurosurgical resection or 
WBRT. All risk factors were entered into univariate analysis 
using the Cox proportional hazards model. Significant risk 
factors were further entered into multivariate analysis, except 
GPA and RPA scores given these measures represent a 
composite of other investigated factors. JMP Pro 13 (SAS 
Institute Cary, NC) was used to perform the analyses. All 
P- values were two- sided with a significance level of 0.05.
Results
Of 1017 eligible patients treated with SRS for BM between 
1994 and 2015, patients with one lesion (543 patients) 
and patients missing survival or baseline data (83 patients) 
were excluded, thereby resulting in 391 patients who were 
included in the analysis.
All patients were analyzed regardless of prior WBRT 
or neurosurgical resection. Baseline characteristics are 
presented in Table 1. Patients with 5 or more BM had 
a higher rate of untreated BM and progressive BM from 
baseline as well as a lower GPA compared to patients 
with 2–4 BM. Of note, there were no significant differ-
ences in total tumor volume between the cohorts.
With a median follow- up of 7.1 months, patients with 
2–4 BM (n = 314) had a median OS of 8.1 months and 
patients with 5 or more BM (n = 77) had a median OS 
of 6.2 months (P = 0.0136) (Fig. 1A). Prognostic factors 
with a significant effect on OS on univariate analysis included 
Table 1. Baseline patient and treatment characteristics.
2–4 (n = 314) 5+ (n = 77) All (n = 391) P- value
Age, median (range) 60 (13–100) 55 (29–100) 59 (13–100) 0.11
Sex
Male 172 (55%) 45 (58%) 217 (56%) 0.56
Female 142 (45%) 32 (42%) 174 (44%)
Histology
Breast adenocarcinoma 46 (15%) 9 (12%) 55 (14%) 0.26
Lung NSCLC 59 (19%) 10 (13%) 69 (18%)
Melanoma 140 (45%) 45 (60%) 185 (48%)
Renal cell carcinoma 25 (8%) 4 (5%) 29 (8%)
Other 39 (13%) 7 (9%) 46 (12%)
KPS median (range) 90 (50–100) 90 (40–100) 90 (40–100) 0.89
GPA, median (range) 2 (0–3.5) 1.5 (0.5–3) 1.5 (0–3.5) <0.0001
RPA
Class 1 46 (15%) 6 (8%) 52 (14%) 0.20
Class 2 247 (80%) 66 (89%) 313 (82%)
Class 3 15 (5%) 2 (3%) 17 (4%)
Brain mets diagnosed 
within 3 months of 
primary
42 (16%) 11 (17%) 53 (16%) 0.88
Increase in # of brain mets 
from baseline to 
treatment
101 (32%) 47 (61%) 148 (38%) <0.0001
Untreated brain mets 48 (15%) 19 (25%) 67 (17%) 0.05
Infratentorial brain mets 113 (36%) 33 (43%) 146 (37%) 0.06
SRS dose, Gy, median 
(range)
18 (12–22) 18 (14–20) 18 (12–22) 0.07
Total tumor volume, cc, 
median (range)
3.36 (0.07–36.02) 3.53 (0.29–81.60) 3.41 (0.071–81.60) 0.43
Total tumor volume, cc
<5 195 (62%) 44 (58%) 239 (61%) 0.67
5–10 58 (19%) 14 (18%) 72 (19%)
>10 60 (19%) 18 (24%) 78 (20%)
NSCLC, Nonsmall Cell Lung Cancer; KPS, Karnofsky Performance Status; GPA, Grade Prognostic Assessment; RPA, Recursive Partitioning Analysis; 
mets, metastases; SRS, Stereotactic Radiosurgery.
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lesion number, total tumor volume, histology, untreated 
BM, KPS, GPA, and RPA. Tumor volume >10 cc had a 
hazard ratio (HR) of 1.451 for worse OS when compared 
to tumor volume <5 cc (P = 0.010) (Fig. 1B). Tumor 
volume was also significantly associated with worse OS 
when analyzed as a continuous variable (P = 0.0314). Breast 
histology had the best OS with melanoma, lung, and other 
categories faring significantly worse (Fig. 1C). Lung primaries 
(nonsmall cell lung cancer) and other histologies (including 
small cell lung cancer, colorectal, prostate, ovarian) had 
the worst outcomes with HRs of 1.557 and 2.463, respec-
tively, in comparison with patients with breast cancer. On 
multivariate analysis, only total tumor volume, KPS, and 
histology remained significant (Table 2).
To further analyze the relationship of tumor volume 
and lesion number, a standard least squared regression 
model was used. There was a statistically significant but 
weak correlation between the two (R2 = 0.045, P < 0.0001). 
The number of BM only accounted for 4.5% of the vari-
ance in total tumor volume. Figure 2 displays this rela-
tionship of volume by lesion number in a box plot.
After excluding 121 patients with prior surgery (n = 77) 
and/or WBRT (n = 58), the difference in median OS 
was not significantly different on univariate (P = 0.0603) 
or multivariate (P = 0.2772) analysis when comparing 
2–4 BM (n = 219) to 5 or more BM (n = 52) (Tables 
S1 and S2). Histology, KPS, GPA, RPA, and total tumor 
volume were significantly associated with OS on univariate 
analysis. On multivariate analysis, total tumor volume 
(both as a categorical and as a continuous variable), KPS, 
and histology remained significant, consistent with the 
primary analysis of all patients.
We further analyzed the data to attempt to develop a 
metric for identifying patients with the worst prognosis 
where consideration of best supportive care may be war-
ranted. Given the median OS of breast cancer histology 
(14.72 months) versus all nonbreast histology (median OS 
7.18 months; P = 0.006), we examined all patients with 
nonbreast cancer. Seventy- eight patients with nonbreast 
histology had OS <3 months. Of these, 21 had total tumor 
volume >10 cc. Nine had total tumor volume >10 cc and 
KPS <80. We found those with total tumor volume >10 cc 
Figure 1. Kaplan–Meier survival curves of (A) number of brain metastases by category (B) tumor volume by category (C) histology (D) risk category.
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and KPS <80 had a median OS of 1.63 months compared 
to 7.87 months for all patients that did not meet all these 
criteria (P = 0.02). The KM survival curves based on these 
criteria are presented in Figure 1D.
Discussion
Many radiation oncologists use lesion number as an impor-
tant consideration when deciding on an optimal treatment 
strategy of SRS versus WBRT for BM. In a survey of 
practicing radiation oncologists by Sandler et al., number 
of lesions was identified as the most important factor in 
decision making for selecting WBRT versus SRS—more 
important than performance status, size of lesions, extrac-
ranial disease status, histology, and patient convenience. 
Furthermore, non- CNS specialists (as defined by patient 
volume) were more likely to pick a lower number for the 
cutoff of when to no longer treat with SRS (mean 5.1 
BM) versus CNS specialists (mean 8.1 BM), with a mean 
cutoff closer to four for minimal volume providers. Most 
Table 2. Univariate and multivariate Cox proportional hazards model of overall survival.
Variables Univariate Multivariate
HR (95% CI) P- value HR (95% CI) P- value
Number of BM treated
2–4 Ref. Ref. Ref. Ref.
5+ 1.396 (1.062–1.810) 0.0176 1.220 (0.903–1.624) 0.1921
Age
≤60 years Ref. Ref. Ref. Ref.
>60 years 1.228 (0.991–1.521) 0.0604 1.201 (0.957–1.505) 0.1143
Sex
Male Ref. Ref. – –
Female 0.877 0.2272 – –
Histology
Breast adenocarcinoma Ref. Ref. Ref. Ref.
Lung NSCLC 1.557 (1.059–2.291) 0.0236 1.664 (1.110–2.497) 0.0134
Melanoma 1.473 (1.059–2.049) 0.0173 1.422 (0.997–2.009) 0.0397
Renal cell carcinoma 1.180 (0.725–1.922) 0.5085 1.053 (0.641–1.730) 0.8395
Other 2.463 (1.596–3.800) <0.0001 1.947 (1.231–3.079) 0.0049
KPS
90–100 Ref. Ref. Ref. Ref.
70–80 1.533 (1.219–1.922) 0.0003 1.417 (1.111–1.802) 0.0052
≤60 2.690 (1.542–4.369) 0.0010 2.340 (1.301–3.912) 0.0059
GPA
0–1 Ref. Ref. – –
1.5–2.5 0.686 (0.537–0.883) 0.0037 – –
3–4 0.514 (0.330–0.777) 0.0013 – –
RPA
Class 1 Ref. Ref. – –
Class 2 1.129 (0.827–1.579) 0.4546 – –
Class 3 2.394 (1.305–4.177) 0.0059 – –
Synchronous BM 1.139 (0.815–1.556) 0.4351 – –
Increase in number of BM 
from baseline to 
treatment
0.908 (0.725–1.131) 0.3911 – –
Untreated BM 1.436 (1.078–1.882) 0.0142 1.321 (0.977–1.757) 0.0701
Infratentorial BM 1.140 (0.915–1.415) 0.2418 – –
SRS dose 0.961 (0.915–1.013) 0.1394 – –
SRS dose
<18 Gy Ref. Ref. – –
≥18 Gy 1.141 (0.870–1.477) 0.3323 – –
Total tumor volume
<5 ccs Ref. Ref. Ref. Ref.
5–10 ccs 1.223 (0.916–1.610) 0.1682 1.326 (0.979–1.768) 0.0678
>10 ccs 1.451 (1.094–1.900) 0.0103 1.641 (1.217–2.186) 0.0014
NSCLC, Nonsmall Cell Lung Cancer; KPS, Karnofsky Performance Status; GPA, Grade Prognostic Assessment; RPA, Recursive Partitioning Analysis; 
mets, metastases; SRS, Stereotactic Radiosurgery.
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radiation oncologists listed four to six lesions as the cohort 
they found most challenging in deciding how to treat [4]. 
However, prior studies as well as our analysis demonstrate 
that although lesion number is an easily quantifiable metric, 
it is not necessarily the best factor in determining optimal 
candidacy for SRS.
In a prospective observational trial (JLGK0901), patients 
with 2–4 BM (n = 531) and 5 or more BM (n = 208) 
had equivalent median survivals of 10.8 months (P = 0.78). 
There was no difference in the rate of neurologic death 
or local recurrence between the two groups [10]. Our 
findings are consistent with these results. Although median 
OS for all patients significantly favored the 2–4 group on 
univariate analysis (8.13 months vs. 6.23 months, 
P = 0.0176), on MVA, the difference was no longer sta-
tistically significant (P = 0.2714). This result was true for 
all patients including those with prior WBRT and/or surgery 
as well as when patients were excluded that had prior 
WBRT and/or surgery. For patients not receiving prior 
WBRT and/or surgery, lesion number was not significant 
on univariate (P = 0.0603) or MVA (P = 0.2772).
Yamamoto et al. concluded that radiosurgery alone for 
patients with 5 or more BM was noninferior to outcomes 
with SRS alone in patients with 2–4 BM. Their group 
further evaluated patients with 10 or more BM treated 
with SRS in a propensity score case- matched analysis and 
found no difference between groups for OS or neurologic 
death as well as other measures such as local recurrence, 
repeat SRS for new lesions, or complications [9]. Additional 
evidence comes from prior retrospective series including 
Chang et al. [14], who found no difference in regard to 
outcomes after SRS for patients with 1–5, 6–10, 11–15 
or even more metastases.
Tumor volume may be more important in terms of 
prognostication than lesion number. In the current series, 
tumor volume >10 cc was associated with worse OS 
(HR = 1.451). Multiple prior series have found similar 
results regarding the association between increasing tumor 
volume and worse outcomes. Bhatnagar et al., Likhacheva 
et al., and Baschnagel et al., demonstrated that tumor 
volume was statistically significantly associated with OS 
while number of BM was not [15–17]. Interestingly, this 
was true in our series of all patients and excluding patients 
with prior WBRT or surgery. Cumulative tumor volume 
was likewise significantly associated with worse survival 
on univariate analysis in JLGK0901.
Secondary factors including female sex, age <65, KPS 
≥80, stable extracranial disease, and the absence of neu-
rologic symptoms were significantly associated with longer 
OS in JLGK0901 [10]. In our analysis, histology and KPS 
(along with tumor volume) were significantly associated 
with OS on MVA. These factors have been studied in 
prior series and components utilized in the graded prog-
nostic assessment and in nomograms. While lesion number 
is often a factor, tumor volume is rarely included in these 
scoring systems [18].
To further investigate the association of the interplay 
of number of BM and volume, we looked at the correla-
tion between the two. While increasing number of BM 
was significantly correlated with tumor volume, it 
accounted for only 5% of the variance. Additionally, we 
identified a high- risk cohort, namely histology other than 
breast cancer, tumor volume >10 cc, and KPS <80. These 
patients had a median OS of <2 months.
This study is limited by its retrospective nature and the 
limited scope of patient data, such as lack of information 
regarding systemic therapies. These data are subject to 
inherent biases including selection bias in that the 5 or 
more BM group could represent a select and more favorable 
cohort. However, the intent of this analysis was to look 
at patients in a clinical setting treated at the discretion of 
the consulting radiation oncologist, and the groups were 
well balanced with the exception of GPA as described above. 
Patients treated over the course of two decades were ana-
lyzed, representing a heterogeneous group with many changes 
in overall approaches to oncologic care throughout this 
time period. However, these results of patients treated at 
a single institution over 20 years have practical implications 
for current management of the increasingly common patient 
presenting with multiple BM, especially in the absence of 
a randomized trial. Arbitrarily using a cutoff of 5 or more 
metastases is not warranted based on this data and should 
not exclude patients from radiosurgery, nor should prior 
WBRT or neurosurgical resection.
Current guidelines have clearly delineated recommen-
dations for patients with 4 or fewer metastases but not 
for patients with 5 or more lesions in regard to SRS 
[19, 20]. A single institution phase III randomized trial 
(NCT01592968) currently enrolling patients with 4 or 
Figure 2. Box plot of tumor volume versus number of brain metastases 
with linear regression.
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more BM to SRS versus WBRT will ideally provide level 
1 evidence regarding optimal management [21].
Ultimately, the decision to treat a patient with more 
than 4 BM with SRS depends on a number of clinical 
and pathologic factors, including systemic therapeutic 
options, prognosis, and the patient’s goals of care. These 
factors should be discussed in a multidisciplinary tumor 
board setting when possible. Tumor volume in conjunction 
with other clinical and pathologic features is likely more 
important in terms of prognostication than lesion number 
alone, and has recently been shown to improve prognostic 
models including disease- specific GPA [22–24].
With the increasingly common use of targeted agents, 
delays in systemic therapy secondary to WBRT could 
ultimately be detrimental to a patient’s outcome. 
Nevertheless, even in the setting of targeted agents, radio-
therapy remains an important treatment for patients with 
BM and could impact OS [25]. Furthermore, immuno-
therapy and targeted agents may lead to better tumor 
control and reduce distant brain failure, rendering SRS 
more impactful [26]. Finally, with close surveillance, 
patients that have regional failure after SRS can undergo 
effective salvage SRS with low morbidity, providing further 
rationale for the upfront use of SRS.
Conclusions
Patients with 5 or more BM treated with SRS have com-
parable OS to those with 2–4 BM, regardless of prior 
WBRT or surgery, and remain good candidates for SRS 
based on the results of this study. While number of lesions 
may be prognostic, total tumor volume may be a more 
important factor in determining OS. Given the side effects 
associated with WBRT and equivalent outcomes with SRS 
alone, our analysis supports offering SRS alone to select 
patients with 5 or more BM with total tumor volume 
<10 cc in clinical practice.
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